Clinical trial
A Phase Ia-Ib Dose-escalation Study Evaluating Safety and Efficacy of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) With Concomitant Capecitabine Chemotherapy for Resectable Carcinoma of Exocrine Pancreas.
NCT01918644 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ia-Ib Dose-escalation Study Evaluating Safety and Efficacy of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) With Concomitant Capecitabine Chemotherapy for Resectable Carcinoma of Exocrine Pancreas.
- Lead sponsor
- University of Wisconsin, Madison
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 8, 2014
- Completion date
- April 26, 2022
- Enrollment
- 21 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
stage ia pancreatic cancer, stage ib pancreatic cancer, stage iia pancreatic cancer, stage iib pancreatic cancer